Anti-Inflammatory Effects of Time-Restricted Feeding

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

27 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-09

Study Completion Date

2023-07-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Time-restricted feeding (TRF) means that a person eats only during certain hours of the day. In other studies, researchers have found that fasting can improve immune system function in healthy people. They want to see if TRF has the same effect on people with psoriasis.

Objective:

To test whether TRF can change metabolism and decrease some markers of inflammation in the blood of people with mild to moderate psoriasis.

Eligibility:

Males ages 18 to 80 with mild to moderate active psoriasis, and healthy volunteers

Design:

Participants will be screened with a medical history and medicine review. They will have a physical exam and blood tests. Their skin will be examined. They will have a nutritional evaluation. Their resting energy expenditure will be measured. For this, a clear plastic ventilation hood will be placed over the head for a short time.

Participants will stay at the NIH Clinical Center for 4 1/2 days. They can watch TV, do work, do schoolwork, and other quiet activities.

A small sensor will be placed under participants skin to measure blood glucose.

For part of the study, participants will be housed in a small room called a metabolic chamber. They will wear a heart monitor.

Participants will walk on a treadmill for 30 minutes each day at a comfortable speed.

For 3 days, participants will eat all their daily calories between 8 am and 2 pm. They will fast for the other 18 hours of the day. They can drink water.

Participants will complete mixed meal tests. They will drink a liquid meal for breakfast. Then they will give blood samples via intravenous (IV) catheter.

Participation will last for 5 days....

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Modified Intermittent Fasting in Psoriasis

NCT04418791

Psoriasis Vulgaris Psoriasis

COMPLETED NA

Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis

NCT05590247

Psoriasis Psoriatic Arthritis

ACTIVE_NOT_RECRUITING NA

Exploratory Clinical Study on Fasting in Psoriasis and Psoriatic Arthritis (RiseFast)

NCT06905028

Psoriasis Arthritis Psoriasis (PsO)

RECRUITING NA

n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis

NCT01876875

Plaque-type Psoriasis Obesity (Body Mass Index >30 kg/m2)

COMPLETED PHASE4

The DIET Trial - Dietetic Intervention in Psoriatic Arthritis

NCT03142503

Arthritis, Psoriatic Metabolic Syndrome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Description:

Fasting and caloric restriction interventions have anti-inflammatory effects, although the underling regulatory controls are poorly characterized. This pilot study will explore transcriptional profiles in various leukocyte populations comparing the effect of time restricted feeding (TRF - 6-Hr feeding/18-Hr fast) to a more conventional dietary regimen (12-Hr feeding/12Hr fast). These regulatory effects will be evaluated in an inflammatory disease (psoriasis) in response to TRF and by comparing the relative response comparing the psoriasis population to a matched TRF control group.

Objectives:

1. Evaluate the effect of TRF on Th17 immunological signatures.
2. Compare the role of TRF on chromatin remodeling on CD4+ T cells, monocytes and neutrophils comparing control and

psoriatic subjects.
3. Evaluate the effect of TRF on glucose and insulin metabolism and overall metabolic flexibility.

Endpoints:

The primary outcome will be the change in the secretion of IL-17 from activated CD4+ T cells from baseline to the end of TRF as a measure of biological reprograming in the psoriasis group and to assess the change in IL-17 release comparing the effects of TRF in the control versus psoriasis groups.

Secondary outcomes are:

1. Evaluate the effect of TRF on chromatin signatures of gene activation (ATACseq) and gene silencing (H3K9me3).
2. Explore the effect of TRF on low-density granulocytes, neutrophils and monocytes.
3. Evaluate whether TRF improves 24-hour glucose levels, glycemic excursions during a meal test and modulate sleeping

and feeding metabolic flexibility as defined by the change in sleeping respiratory exchange ratio from the daytime. (24-hr

substrate oxidation as defined by the averaged RER)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Systemic Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control group

Age (+/-5 yrs) and BMI (+/- 5 kg/m2) matched control male subjects for inclusion in the control group

No interventions assigned to this group

psoriasis group

Males between the ages of 18 and 70 with mild to moderate active psoriasis by PASI score for inclusion in psoriasis group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males between the ages of 18 and 80 with mild to moderate active psoriasis by PASI score for inclusion in psoriasis group
* Age (plus or minus 10 yrs) and BMI (plus or minus 5 kg/m\^2) matched control male subjects for inclusion in the control group.
* Ability to provide informed consent
* Willingness and ability to participate in study procedures

Exclusion Criteria

* Severe psoriasis by PASI (Psoriasis Area and Severity Index) score \> 12
* Treatment with systemic biologic immune modifying agents within the last 2 months.
* Currently on treatment for allergies or other inflammatory diseases.
* Has taken Vitamin B or tryptophan supplementation within 2 weeks of participation.
* Unwillingness/inability to provide informed consent.
* Individuals with known history of type 1 and 2 diabetes mellitus or other metabolic conditions that would interfere with study parameters including chronic kidney disease, chronic liver disease, history of hypoglycemia
* On treatment with medication that would interfere with study parameters including anti-hyperglycemic medications, systemic steroids, adrenergic-stimulating agents, other medications known to affect sleep, circadian rhythms or metabolism.
* Caffeine in excess of three 8 oz cups per day.
* Factors that affect circadian rhythm including individuals who perform overnight shift work, irregular sleep and/ or eating schedules, regularly fast for more than 15 hours/ day
* Regular use of tobacco product within last 3 months.
* Consuming more than 3 servings of alcohol/ day
* Engaged in competitive sports training
* Moderate to severe claustrophobia
* Unstable weight with more than 5% body weight change in last 3 months
* Food allergies or intolerances or dietary patterns that would prohibit consumption of the metabolic diet or mixed meal test.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No